Business Wire

XPRIZE Plans to Continue Lunar XPRIZE Mission

Jaa

Today, XPRIZE announced their plan to continue the Lunar XPRIZE mission, with a re-launch of a new Lunar-focused competition.

Effective today, the Lunar XPRIZE will operate as a non-cash competition. Over the next few months, XPRIZE will define new parameters for companies to compete in the prize.

Also, effective today, XPRIZE is seeking a new Title Sponsor for the Lunar XPRIZE competition, taking over for the support provided by Google during the past decade.

“We are extraordinarily grateful to Google for funding the $30 million Google Lunar XPRIZE between September 2007 and March 31st, 2018. While that competition is now over, there are at least five teams with launch contracts that hope to land on the Lunar surface in the next two years,” said Peter H. Diamandis, M.D., XPRIZE founder and executive chairman. “Because of this tremendous progress, and near-term potential, XPRIZE is now looking for our next visionary Title Sponsor who wants to put their logo on these teams and on the lunar surface.”

“Over the last decade the Google Lunar XPRIZE teams raised over $300 million through corporate sponsorships, government contracts and venture capital,” said Chanda Gonzales-Mowrer, senior director of prizes at XPRIZE. “These space entrepreneurs are developing long-term business models around lunar transportation, and we cannot give up on them now. I am confident that one of these companies will land on the Moon in the near future and am excited for the next chapter of this new space race.”

XPRIZE has heard from many of the major Google Lunar XPRIZE teams who have expressed their support and desire for the competition to proceed with or without a monetary prize purse:

  • “We applaud XPRIZE’s decision to continue the Lunar XPRIZE, with or without a title sponsor,” said Bob Richards, founder & CEO of Moon Express. “While we plan to win this Moon race and are committed to carrying the Lunar XPRIZE logo, the real opportunity is in opening the lunar frontier and the multibillion dollar industry that follows.”
  • “The previous Google Lunar XPRIZE competition showed the world how the concept of a race was necessary to advance the private space industry to a new level,” said Takeshi Hakamada, founder and CEO of ispace, the management company for HAKUTO. “It raised public interest in space and led to activations from companies not traditionally involved in space. We believe a new competition would again elevate our industry to an even higher level, so we eagerly welcome a new Lunar XPRIZE.”
  • “The Google Lunar XPRIZE served as an excellent early catalyst to get new people, partners and money involved,” said Rahul Narayan, CEO and founder of TeamIndus. “With the renewed interest in beyond Earth-orbit exploration by multiple large government space agencies, a new Lunar XPRIZE will be a perfectly timed platform with the chances of multiple successful launches being much higher than before.”

The new Lunar XPRIZE Title Sponsor would be responsible for putting up one or more contingent purses for the winners. The Title Sponsor would have the benefit of having their name and branding incorporated into the competition, and in success, on the surface of the Moon. For more information on becoming a titled sponsor, visit xprize.org/lunarxprize or email sponsorship@xprize.org.

ABOUT XPRIZE

XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. XPRIZE utilizes a unique combination of gamification, crowd-sourcing, incentive prize theory, and exponential technologies as a formula to make 10x (vs. 10%) impact in the grand challenge domains facing our world. XPRIZE’s philosophy is that—under the right circumstances— igniting rapid experimentation from a variety of diverse lenses is the most efficient and effective method to driving exponential impact and solutions to grand challenges. Active competitions include the Lunar XPRIZE, the $20M NRG COSIA Carbon XPRIZE, the $15M Global Learning XPRIZE, the $10M ANA Avatar XPRIZE, the $7M Shell Ocean Discovery XPRIZE, the $7M Barbara Bush Foundation Adult Literacy XPRIZE, the $5M IBM Watson AI XPRIZE, the $1.75M Water Abundance XPRIZE and the $1M Anu and Naveen Jain Women’s Safety XPRIZE. For more information, visit www.xprize.org.

Contact information

XPRIZE Media Contact:
Katherine Schelbert, 424.835.3127
katherine.schelbert@xprize.org

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30Tiedote

www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re

The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00Tiedote

The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and

Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22Tiedote

Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07Tiedote

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type

European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection25.6.2018 15:03Tiedote

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIC/FTC/TAF combines the potency of the novel integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF), a guidelines-recommended dual nucleoside reverse transcriptase inhibitor (NRTI) backbone. Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years. In Europe, BIC/FTC/TAF is indicated as a complete regimen for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or tenofovir. No dosage adjustment of BIC/FTC/TAF is required in patien

AlipayHK and GCash Launch Cross-Border Remittance Service Powered by Alipay’s Blockchain Technology25.6.2018 15:00Tiedote

AlipayHK and GCash today announced the launch of a cross-border remittance service through their e-wallet platforms, powered by cutting-edge blockchain technology developed by Alipay, the online payment platform operated by Ant Financial Services Group (“Ant Financial”, “Ant”). This is the first blockchain-based cross-border digital wallet remittance service globally, offering a fast, secure, convenient, transparent and low-cost way to transfer money directly between individuals in Hong Kong and the Philippines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005561/en/ Mary Grace (left), who has been working in HK for 22 years, demonstrated how it took her 3 seconds to transfer money to her family back in the Philippines, through the mobile payment app AlipayHK (Photo: Business Wire) Alipay has applied blockchain technology to streamline the remittance process, radically improving the speed of delivery, enhancing trans

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme